DeniLA: Comprehensive demographics and clinical profile of NSCLC patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns - DeniLA

Study identifier:D133FR00224

ClinicalTrials.gov identifier:NCT07109154

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

DeniLA: Comprehensive demographics and clinical profile of NSCLC patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns Observational study (prospective and survey); evaluation patterns of choice in first line treatment of metastatic NSCLC

Medical condition

Lung Neoplasms

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 29 Nov 2025
Estimated Primary Completion Date: 30 Apr 2027
Estimated Study Completion Date: 30 Apr 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria